Thus, calcifediol may be an alternative to optimize 25(OH)D status and should beconsidered in specific situations, including obesity, malabsorption syndromes(e.g., Crohn’s disease, celiac disease, and cystic fibrosis),bariatric surgery, chronic liver diseases, and the use of drugs that interfere withthe hepatic cytochrome P-450 enzyme system, such as corticosteroids,anticonvulsants, and antiretrovirals (8,11,15). Here, CYP4F3 is linked to obesity disorder.